Protea Announces Collaborative Partnership With Protein Metrics


Protea Biosciences Group, Inc. recently announced it is collaborating with Protein Metrics Inc., a premier provider of software solutions for the comprehensive characterization of proteins, to advance new analytical capabilities for use in the development of protein biotherapeutics.

“We are positioning Protea to be a leader in the next generation of bioanalytics, focused on the needs of the biotherapeutics industry,” said Greg Kilby, PhD, Protea’s Vice President and Chief Operating Officer. “Our Protein Metrics collaboration will provide Protea access to advanced software for comprehensive protein characterization, PTM analysis, and sequence variant analysis. We will combine our technologies, including our proprietary LAESI mass spec imaging platform, with Protein Metrics software to provide novel, big data services to identify, characterize, and quantify biologically important molecules. Biopharma is in need of these new bioanalytical capabilities.”

“The rapid adoption of our suite of software is entirely thanks to the input from our customers who have helped us design tools that are directly applicable and tailored to their needs. We are delighted to partner with Protea Biosciences and are looking forward to seeing our software advance the results they provide their clients,” added Chris Becker, President and CEO of Protein Metrics.

Protea Biosciences Group, Inc. provides innovative bioanalytical solutions to the pharmaceutical and life science industries by applying the company’s proprietary technology to identify and characterize the proteins, metabolites, lipids, and other biologically active molecules that are the byproducts of all living cells and life forms. Protea is the leader in mass spectrometry imaging services (MSI), providing a revolutionary capability that enables the identification and spatial display of biologically active molecules in tissue and cells. MSI can be performed without sample preparation, labeling or antibody techniques, thereby integrating for the first time direct identification of molecules with anatomic pathology. For more information, visit www.proteabio.com.

Protein Metrics Inc. is a privately held company serving biopharmaceutical development professionals. The company focuses on the analysis of mass spectrometric and other analytical data on proteins, peptides, and glycans. Seeking to ensure that software to analyze mass spec and other analytical data keeps pace with the rapid advances in instrumentation, Protein Metrics leverages its experience in mass spectrometry, computer science, and bioinformatics to make analytical results more complete, sensitive, accurate, and easier to achieve. For more information, visit www.proteinmetrics.com.